Colorectal Cancer | Specialty

Efficacy of Adjuvant Therapy in Stage II Colon Cancer

November 21st 2018

Current Role of Adjuvant Therapy for Colon Cancer

November 21st 2018

Dr. Cercek on Chemotherapy Resistance in dMMR Rectal Cancer

November 20th 2018

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chemotherapy resistance in mismatch repair deficient rectal cancer.

Novel Agent Active Across Heavily Pretreated HER2+ Tumors

November 17th 2018

The novel bispecific antibody ZW25 induced a disease control rate of 82% in heavily pretreated patients across several HER2-positive tumor types, according to phase I study results presented at the 2018 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium.

Novel Drug Combination Shows Early Activity in Microsatellite Stable CRC

November 17th 2018

Pixatimod (PG545) in combination with the PD-1 inhibitor nivolumab (Opdivo) may benefit patients with advanced bowel cancers, including a small subset of those with colorectal cancer considered to be microsatellite stable.

Future Research and the Clinical Management of mCRC

November 16th 2018

Additional Considerations for Targeted Therapy in mCRC

November 16th 2018

Tumor Sidedness and Treatment Considerations in mCRC

November 16th 2018

RAS Mutation Testing in mCRC

November 16th 2018

Frontline Management of Newly Diagnosed mCRC

November 16th 2018

Dr. Benson on the Clinical Utility of cfDNA in Colorectal Cancer

November 16th 2018

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the clinical utility of cell-free DNA (cfDNA) in guiding treatment decisions for patients with colorectal cancer (CRC).

Rationale for Pembrolizumab Plus mFOLFOX6 in Advanced CRC

November 15th 2018

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses the rationale behind the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer.

Dr. O'Connor on Real-World Results With Regorafenib in mCRC

November 13th 2018

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses real-world results with regorafenib (Stivarga) in the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Bekaii-Saab on the Impact of Next-Generation Sequencing in mCRC

November 9th 2018

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the utility of next-generation sequencing in metastatic colorectal cancer (mCRC).

Obesity Impact Draws Increased Scrutiny in GI Malignancies

November 6th 2018

Obesity is associated with an increased risk of early-onset colorectal cancer among women and correlates with higher rates of cancer resections in gastrointestinal malignancies across age groups.

Dr. McCollum on the Clinical Utility of Regorafenib in mCRC

November 2nd 2018

A. David McCollum, MD, attending oncologist, Baylor University Medical Center, discusses the clinical utility of regorafenib (Stivarga) in metastatic colorectal cancer (mCRC).

Dr. Cercek on Induction Chemotherapy in Mismatch Repair Deficient Rectal Cancer

October 29th 2018

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses induction chemotherapy in patients with mismatch repair deficient rectal cancer.

Real-World Results Reveal Regorafenib Tolerability in mCRC

October 29th 2018

Juan Manuel O’Connor, MD, discusses the final results of the CORRELATE regorafenib study in patients with metastatic colorectal cancer, emphasizing the importance of real-world data.

Dr. Lenz on the Benefit of Regorafenib in CRC

October 26th 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the benefit of regorafenib (Stivarga) in the treatment of patients with colorectal cancer (CRC).

Neoadjuvant Nivolumab Plus Ipilimumab Active in dMMR Early-Stage Colon Cancer

October 23rd 2018

First results from a study of neoadjuvant ipilimumab plus nivolumab in patients with early-stage colon cancer found a major pathologic response achieved in all 7 patients with mismatch repair deficient tumors.